New Jersey

__NOT_FOUND__

A science-driven, patient-centered approach guides this fertility program, uniting clinical excellence with advanced laboratory capabilities. A multidisciplinary team of physicians, embryologists, and genetic specialists collaborates across every cycle—from initial evaluation and diagnostic testing through stimulation, retrieval, and follow-up care. The emphasis is on evidence-based protocols, meticulous lab work, and transparent communication to help patients understand options and take informed steps toward building a family.
Comprehensive fertility care with genetic insight pairs with cutting-edge lab technology to optimize outcomes while safeguarding safety and well-being. The program offers a full spectrum of treatments, sophisticated genetic testing, and supportive services such as counseling and financial planning to improve access to care.

In Vitro Fertilization (IVF)
Intrauterine Insemination (IUI)
Intracytoplasmic Sperm Injection (ICSI)
Preimplantation Genetic Testing (PGT)
Egg Freezing / Oocyte Cryopreservation
Egg and Sperm Donor Options
Gestational Carrier Support
LGBTQIA+ Family Building
Fertility Testing and Counseling
Financial Counseling, Insurance Support, and Financing Options

Located in Livingston, New Jersey, the clinic is powered by a team committed to advanced laboratory science and transparent patient education. The laboratory environment emphasizes embryo biology, genetics, and the integration of stem cell science with reproductive medicine to guide treatment decisions. This research-informed framework translates into care that respects diverse family-building goals and provides clear, evidence-based options.
Beyond clinical options, the practice highlights inclusive care, donor and carrier pathways, and dedicated resources to help patients navigate insurance and financing. By blending scientific rigor with compassion and a transparent care pathway, patients pursue their fertility goals with confidence.

Reimagining pharmaceutical innovation, this company is at the forefront of healthcare evolution, dedicated to transforming patient access to life-altering therapies. Based in the strategic locale of Jersey City, it leverages advanced biotechnology to deliver a robust lineup of FDA-approved biosimilars and biologics that reshape treatment standards in the U.S.

Specializing in high-quality biosimilars, their portfolio includes critical therapies like INFLECTRA®, TRUXIMA®, and HERZUMA®. Noteworthy among their innovations is ZYMFENTRA®, acclaimed as the first subcutaneous infliximab available in the U.S., offering enhanced patient convenience and optimized therapeutic outcomes.

With a commitment to expanding therapeutic horizons, this enterprise boasts a promising pipeline of biosimilars, including candidates like CT-P41 and CT-P47. Their dedication extends to regulatory milestones, with OMLYCLO® distinguished as the sole interchangeable biosimilar with XOLAIR®.

Powered by a customer-centric philosophy and driven by a visionary approach, the company is a beacon of advancement in the pharmaceutical landscape. It consistently prioritizes broadening patient access to innovative treatments, underpinned by a strong heritage and strategic global partnerships.


Expertise in high-standard biologics and biosimilars
Innovative product offerings tailored for patient convenience
Strategic U.S. positioning in Jersey City for nationwide impact
Commitment to regulatory achievements and therapy access

Located in Newark, New Jersey, this pediatric health system delivers specialized care for children from birth through adolescence, coordinating diagnosis, treatment, and family support within a family-centered framework. A core focus is stem cell–based therapies offered through dedicated hematology-oncology programs, including bone marrow transplantation for cancer and blood disorders, supported by a multidisciplinary team of pediatric specialists and disease-specific clinics.
Key services and programs include:

Valerie Fund Children’s Center for Cancer and Blood Disorders: New Jersey's largest center for pediatric cancers and blood disorders, delivering comprehensive stem cell–driven care and coordinated support.
Children’s Heart Center: The state's leading center for complex congenital and acquired heart conditions, offering medical and surgical treatment options.
Neonatal Intensive Care Unit (NICU) – Level IV: Regional perinatal center with ECMO therapy for infants in severe respiratory distress.
Pediatric Anesthesia and Sedation: Specialized perioperative care tailored to children’s needs.
Preventive Health Programs: Beth Greenhouse community initiatives and KidsFit pediatric weight management to support long-term wellness.
Pediatric Psychiatry: Inpatient and outpatient services spanning behavioral health and mood disorders for youth.
Child Life Services: Therapeutic play and coping strategies to reduce stress around medical experiences.

As part of RWJBarnabas Health, New Jersey's largest academic health system, the network provides broad access to pediatric subspecialists and coordinated care across campuses. Multilingual resources, including the Chinese Medical Program, help families navigate care, while dedicated patient-services teams support appointments, education, and follow-up. The organization emphasizes preventive care, early intervention, and a seamless continuum of inpatient and outpatient services for children and their families.
With advanced facilities, research-backed care, and a patient- and family-centered approach, this pediatric health system stands as a trusted partner for families across New Jersey seeking high-quality, child-first care.